Our unique collection of technologies/capabilities places us at the forefront of HFpEF research. Using these strategies, our aims are as follows:
- Determine key mechanistic underpinnings in each subclass of HFpEF.
- Develop novel management strategies and treatment guidelines to treat each HFpEF subclass (with Dr Sean Lal, co-Director of HFpEF clinic and Director of Sydney Heart Bank).
- Develop novel therapeutics to improve HFpEF outcome (with Dr Xuyu Liu, HRI).
Outcomes: New management guidelines and therapeutic agents for HFpEF, the most common form of heart failure globally that currently has no approved pharmacotherapies.